Syngene To Spend Rs 900 Crore On Capex In FY22 As It Looks To Expand
Syngene International Ltd. plans to spend Rs 900 crore on capital expenditure in the ongoing financial year as it focuses on growth.
“Capex and opex investments are a sign of confidence in the business and the business model,” Jonathan Hunt, the company's managing director and chief executive officer told BloombergQuint's Niraj Shah in an interaction, adding the investments aren't costs but essential for growth.
The contract researcher's net profit after tax rose 33% year-on-year to Rs 1,606 crore in the quarter ended March. Hunt said capex incurred over the last five years helped them achieve a profit margin of over 30%.
For FY22, Syngene expects to operate at near-normal levels, with its business being categorised as an essential service. As a result, the company expects to report similar margins and revenue growth in the mid-teens in the ongoing fiscal and over the longer term.
The recent renewal of the long-standing partnership with Bristol-Myers Squibb for another decade is a real “bellwether event” for Syngene, Hunt said as it provides them with long-term business visibility. The relationship, he said, will undergo “strong expansion” than in the past decade, and could result in a 40% upside in revenue.
“We're an upper-quartile performer from a margin point of view on a globalised basis,” the CEO said, adding many of his peers have lower margins. This could be attributed to the sophistication of the services and our ability to integrate, he said.
Syngene expects its clients in the biotech or pharmaceutical industry to look at building business models that are a combination of in-house and outsourcing partnerships.
The outsourcing, he said, wouldn't just aim for labour-cost arbitrage but will look at increasing sophistication and value addition. Hunt said Syngene's ability to integrate and add intellectual value and not just get the work done on an operating cost arbitrage will make a difference.
Watch the full interview here-
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.